Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

477.40 +9.02 (+1.93%)
Streaming Delayed Price Updated: 10:51 AM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
69 70 Next >
News headline image
Moderna’s Second Act: Analyzing the 2026 Pipeline Pivot and Recent Stock Surge
Date: January 7, 2026 Introduction Moderna, Inc. (NASDAQ: MRNA), once the definitive poster child of the COVID-19 pandemic response, is currently undergoing one of the most significant pivots in the... 
Via PredictStreet
Topics Economy Initial Public Offering Intellectual Property
News headline image
Stocks making big moves yesterday: Herbalife, Vertex Pharmaceuticals, Micron, Amkor, and Palantir Technologies
Check out the companies making headlines yesterday: 
Via StockStory
Topics Artificial Intelligence
News headline image
Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why
Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 3.8% in the afternoon session after Wolfe Research upgraded the stock from "Peer Perform" to "Outperform" and issued a $548 price... 
Via StockStory
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Compelling Value Stock Candidate ↗
Via Chartmill
News headline image
My 10 Top Stocks to Buy to Start the New Year Off Right ↗
Investing in a few of these players could increase the diversification of your portfolio. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
BofA Unveils Q1 2026 Top Stock Picks: High-Conviction Bets on AI Infrastructure and Health Care Valuations
As the opening bells of 2026 ring across Wall Street, Bank of America Securities has released its highly anticipated "Top 10 U.S. Stock Ideas for Q1 2026." The report, a cornerstone for institutional... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
The Best Stocks to Invest $1,000 in to Start the New Year Off Right ↗
These three stocks could make 2026 a happy new year for investors. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Stay informed with the top movers within the S&P500 index on Tuesday. ↗
Via Chartmill
News headline image
Discover which S&P500 stocks are making waves on Tuesday. ↗
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
News headline image
2 Growth Stocks to Buy For 2026 and Beyond ↗
Neither had a great year in 2025, but the future is looking bright. 
Via The Motley Fool
Topics Economy
News headline image
2 Nasdaq 100 Stocks Worth Investigating and 1 We Turn Down
The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like profitability concerns, rising costs, or... 
Via StockStory
Topics Electric Vehicles World Trade
News headline image
3 Supercharged Growth Stocks to Buy and Hold Into the 2030s ↗
Growth stocks fall in and out of favor with investors, but quality businesses are always worth buying. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Forget Moderna Stock, This is a Much Better Buy ↗
This stock is a great choice for cautious and aggressive investors. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The $1.7 Billion Pivot: Agios Pharmaceuticals (AGIO) and the New Frontier of Oral Thalassemia Therapy
On December 23, 2025, the biotechnology landscape shifted for thousands of patients living with chronic anemia. The U.S. Food and Drug Administration (FDA) granted approval to AQVESME (mitapivat),... 
Via PredictStreet
Topics Economy
News headline image
Is CRISPR Therapeutics Stock Yesterday's News? ↗
The biotech sells blood disorders treatment, Casgevy. 
Via The Motley Fool
News headline image
Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Moderna (MRNA): The “Act 2” of an mRNA Pioneer – A 2025 Deep Dive
As of December 22, 2025, Moderna, Inc. (NASDAQ: MRNA) stands at a critical juncture in its corporate evolution. Once the poster child for the biotechnology industry’s rapid response to the global... 
Via PredictStreet
Topics Earnings Initial Public Offering Intellectual Property
News headline image
Vertex Pharmaceuticals Inc (NASDAQ:VRTX): A GARP Case Study in Affordable Growth ↗
Vertex Pharmaceuticals (VRTX) exemplifies GARP investing, offering strong earnings growth, top profitability, and a debt-free balance sheet at a reasonable market valuation. 
Via Chartmill
News headline image
2 Cash-Producing Stocks to Consider Right Now and 1 We Find Risky
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
News headline image
Is CRISPR Therapeutics a Buy, Sell, or Hold in 2026? ↗
Next year could be crucial for the company as sales for its only approved treatment could take off. 
Via The Motley Fool
News headline image
2 Reasons to Watch VRTX and 1 to Stay Cautious
Since June 2025, Vertex Pharmaceuticals has been in a holding pattern, posting a small return of 0.5% while floating around $450.68. The stock also fell short of the S&P 500’s 13.6% gain during that... 
Via StockStory
Topics Stocks
News headline image
From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
Issued on behalf of Avant Technologies Inc. 
From USA News Group
Via GlobeNewswire
News headline image
12 Days of Investing: My Top 12 Stocks to Buy Before 2026 ↗
The following players span a variety of industries, so if you pick up more than one, you may gain in diversification. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Vertex Pharmaceuticals (NASDAQ:VRTX) Combines Strong Growth with Technical Breakout Potential ↗
Vertex Pharmaceuticals (VRTX) shows strong growth fundamentals and a positive technical breakout setup, combining high earnings forecasts with a promising stock chart pattern. 
Via Chartmill
News headline image
2 Healthcare Stocks to Buy Ahead of the New Year ↗
These companies could innovate their way to success. 
Via The Motley Fool
News headline image
1 Large-Cap Stock to Consider Right Now and 2 Facing Challenges
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth... 
Via StockStory
News headline image
Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth
As 2025 draws to a close, a powerful undercurrent of technological innovation, extending far beyond the pervasive influence of artificial intelligence, is demonstrably reshaping the global stock... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
News headline image
Down 10%, Should You Buy the Dip on Vertex Pharmaceuticals? ↗
The stock has fallen from a peak back in April. 
Via The Motley Fool
News headline image
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
69 70 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.